Pharmacological Therapy of Cardiac Arrhythmias: Atrial Fibrillation, Current Treatment and Novel Agents
Mohan N. Viswanathan, M.D.
Dr. Viswanathan is Assistant Professor of Medicine, Division of Cardiology/Cardiac Electrophysiology, University of Washington, Seattle, WA.
Within the past 12 months, Dr. Viswanathan reports receiving consulting fees from Sanofi-Aventis and speaking honoraria from Biotronik, Inc.
Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose.
Estimated time to complete:
Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Upon completion of this Cyberounds®
, you should be able to:
- Discuss the extent of the clinical problem of atrial fibrillation
- Describe the mechanisms underlying the generation of the cardiac action potential, the ion channels and the factors involved in generating the excitation impulse
- Enumerate the leading ideas about the electrophysiological mechanisms underlying the development of atrial fibrillation
- Apply the currently available antiarrhythmic medications that are used as rhythm control agents to treat atrial fibrillation, and be able to categorize them via the Vaughan Williams antiarrhythmic classification system
- Discuss a few new agents that have just become available or will become available or are under development for atrial fibrillation and the strategies to limit the side effects of the currently available agents.